rapid
progress
coronaviru
diseas
increas
burden
health
system
necessit
identif
paramet
sever
infect
help
monitor
prognos
develop
treatment
algorithm
review
aim
investig
associ
lymphocyt
count
crp
ldh
ddimer
sever
form
review
conduct
accord
prefer
report
item
systemat
review
metaanalys
prisma
guidelin
databas
medlinepubm
whovirtu
health
librari
vhl
sciencedirect
use
systemat
search
random
effect
model
use
estim
pool
standard
mean
differ
smd
correspond
confid
interv
ci
use
openmeta
analyst
softwar
total
studi
patient
fulfil
elig
criteria
includ
metaanalysi
analysi
reveal
lymphocyt
count
significantli
lower
patient
sever
form
smd
p
valu
also
analysi
smd
show
patient
sever
significantli
higher
serum
level
crp
smd
p
valu
ddimer
smd
p
valu
ldh
smd
p
valu
low
lymphocyt
count
high
level
crp
ldh
ddimer
associ
sever
laboratori
marker
could
use
clinic
indic
worsen
ill
poor
prognosi
decemb
wuhan
capit
central
china
hubei
provincehad
wit
emerg
new
viru
coronavirida
famili
caus
sever
case
sever
respiratori
diseas
viru
name
world
health
organ
sever
acut
respiratori
syndrom
novel
coronaviru
diseas
caus
viru
coronaviru
diseas
diseas
kept
spread
dramat
reach
provinc
china
countri
around
world
forc
declar
global
pandem
th
march
despit
effort
done
contain
diseas
spread
countri
around
world
caus
signific
burden
level
health
facil
well
econom
burden
intern
system
transmit
infect
respiratori
droplet
infect
patient
fomit
surfac
reach
conjunctiva
respiratori
mucosa
incub
period
usual
rang
day
exposur
patient
may
infecti
anim
human
transmiss
still
investig
know
similar
coronavirus
found
bat
rodent
bird
peopl
infect
experienc
mild
moder
respiratori
ill
cough
short
breath
commonest
symptom
approxim
patient
develop
sever
diseas
complic
like
acut
respiratori
distress
syndrom
respiratori
failur
acut
liver
injuri
acut
kidney
injuri
cardiovascular
complic
septic
shock
multiorgan
failur
older
peopl
underli
comorbid
like
diabet
chronic
respiratori
diseas
cardiovascular
diseas
immunecompromis
patient
higher
risk
develop
sever
diseas
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
certifi
peer
review
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
patient
sever
diseas
complic
requir
special
care
admiss
intens
care
unit
icu
mechan
ventil
howev
wide
gap
total
popul
number
intens
care
bed
avail
ad
burden
icu
servic
cost
hospit
around
total
drug
cost
equip
lab
investig
research
still
work
find
definit
treatment
ongo
trial
antivir
antiinflammatori
antimalari
drug
hydroxylchloroquin
sulfat
chloroquin
phosphat
product
use
certain
hospit
patient
diagnosi
depend
evalu
risk
contact
infect
patient
clinic
sign
symptom
polymeras
chain
reaction
test
viral
rna
respiratori
sampl
investig
use
evalu
patient
condit
predict
sever
outcom
diseas
complet
blood
count
ddimer
procalcitonin
creactiv
protein
crp
lactat
dehydrogenas
ldh
two
recent
metaanalys
show
increas
procalcitonin
valu
thrombocytopenia
associ
higher
risk
sever
studi
suggest
lymphocyt
count
ddimer
crp
ldh
role
prognosi
howev
best
knowledg
metaanalysi
biomark
therefor
object
review
assess
associ
sever
laboratori
marker
take
consider
diseas
burden
limit
resourc
capac
health
facil
crucial
find
paramet
support
clinic
condit
risk
assess
aid
anticip
sever
complic
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
search
strategi
inclus
criteria
metaanalysi
follow
prefer
report
item
systemat
review
metaanalys
prisma
statement
observ
studi
report
suffici
inform
lymphocyt
count
crp
ldh
ddimer
level
sever
nonsever
patient
clear
definit
sever
ill
includ
analysi
calcul
standard
mean
differ
smd
estim
exclus
criteria
case
report
editori
letter
abstract
studi
without
suffici
data
interest
two
studi
patient
popul
studi
complet
data
includ
avoid
duplic
titl
abstract
articl
retriev
search
screen
potenti
inclus
review
potenti
relev
studi
review
full
text
inclus
accord
defin
elig
criteria
data
extract
independ
review
use
data
extract
form
qualiti
studi
assess
use
newcastl
ottawa
scale
dispar
among
review
step
resolv
discuss
consensu
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
statist
analys
carri
openmeta
analyst
softwar
version
analysi
pool
smd
calcul
randomeffect
model
due
notabl
heterogen
metaanalysi
statist
heterogen
assess
statist
public
bia
determin
egger
test
visual
examin
funnel
plot
characterist
studi
schemat
flow
studi
identif
select
process
present
figur
summari
data
includ
studi
shown
tabl
sever
determin
base
composit
respiratori
distress
hypoxia
andor
hypoxemia
three
studi
american
thorac
societi
guidelin
communityacquir
pneumonia
one
studi
youden
index
one
studi
guidelin
expert
chines
group
one
studi
nonsurviv
one
studi
diseas
progress
one
studi
oxygen
satur
one
studi
requir
icu
admiss
one
studi
requir
supplement
oxygen
one
studi
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
analysi
smd
crp
two
group
patient
pool
effect
size
show
crp
level
significantli
higher
patient
sever
patient
nonsever
smd
ci
p
figur
detect
slight
public
bia
detect
base
visual
examin
funnel
plot
result
egger
test
p
figur
b
duval
tweedi
trim
fill
method
indic
potenti
miss
studi
three
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
analysi
smd
ldh
two
group
patient
pool
effect
size
show
ldh
level
significantli
higher
patient
sever
patient
nonsever
smd
ci
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
addit
clinic
criteria
great
benefit
laboratori
marker
sever
infect
help
monitor
prognosi
use
develop
workup
treatment
algorithm
metaanalysi
investig
associ
sever
sever
biomark
analysi
show
patient
poor
outcom
like
lymphopenia
shown
figur
base
sever
studi
suggest
immun
system
impair
diseas
might
damag
lymphocyt
studi
show
particular
decreas
subset
lymphocyt
higher
naiv
cell
memori
cell
sever
case
higher
naiv
memori
cell
ratio
indic
immun
system
impair
sever
result
cytokin
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
storm
bodi
gener
seri
immun
respons
caus
chang
peripher
white
blood
cell
level
crp
inflammatori
marker
notic
higher
sever
case
nonsev
case
increas
level
cytokin
chemokin
neutrophil
lymphocyt
ratio
nlr
sever
case
suggest
possibl
hyperinflammatori
respons
role
pathogenesi
ddimer
level
elev
patient
sever
diseas
may
rais
suspicion
underli
abnorm
blood
coagul
function
effect
ddimer
widen
includ
correl
sever
diseas
also
mortal
percentag
shown
zhou
f
et
al
studi
wuhan
china
found
ddimer
level
microgramml
associ
fatal
outcom
gao
et
al
show
clinic
benefit
ddimer
level
predict
sever
diseas
increas
combin
along
level
also
level
ldh
inflammatori
marker
show
similar
correl
mortal
percentag
ddimer
find
studi
need
consid
context
limit
studi
found
asia
wherea
nowaday
major
case
unit
state
europ
due
limited
avail
data
variabl
definit
diseas
sever
among
studi
need
studi
explor
clarifi
prognost
role
well
precis
mechan
underli
chang
biomark
patient
sever
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
avail
data
materi
dataset
gener
studi
avail
correspond
author
reason
request
compet
interest
author
declar
compet
interest
authorfund
grant
medrxiv
licens
display
preprint
perpetu
certifi
peer
review
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
